Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $172,567.26 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares in the company, valued at approximately $1,475,503.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock traded up $0.17 on Wednesday, reaching $19.96. The company had a trading volume of 219,660 shares, compared to its average volume of 107,128. The firm has a market cap of $746.90 million, a price-to-earnings ratio of 12.58 and a beta of -0.26. The firm’s 50-day moving average price is $16.53 and its two-hundred day moving average price is $15.83. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter worth about $636,000. The Manufacturers Life Insurance Company grew its stake in shares of Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter worth approximately $79,000. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after acquiring an additional 13,742 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares during the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright increased their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer increased their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.